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Kaposi’s sarcoma-associated herpesvirus (KSHV) infection is correlated with three human malignancies and can establish life-
long latent infection in multiple cell types within its human host. In order to establish and maintain infection, KSHV utilizes
multiple mechanisms to evade the host immune response. One such mechanism is the expression of a family of genes with ho-
mology to cellular interferon (IFN) regulatory factors (IRFs), known as viral IRFs (vIRFs). We demonstrate here that KSHV
vIRF1, -2, and -3 have a differential ability to block type I interferon signaling mediated by Toll-like receptor 3 (TLR3), a receptor
we have previously shown to be activated upon KSHV infection. vIRF1, -2, and -3 inhibited TLR3-driven activation of IFN tran-
scription reporters. However, only vIRF1 and vIRF2 inhibited increases in both IFN- message and protein levels following
TLR3 activation. The expression of vIRF1 and vIRF2 also allowed for increased replication of a virus known to activate TLR3
signaling. Furthermore, vIRF1 and vIRF2 may block TLR3-mediated signaling via different mechanisms. Altogether, this report
indicates that vIRFs are able to block IFN mediated by TLRs but that each vIRF has a unique function and mechanism for block-
ing antiviral IFN responses.
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a gamma-herpesvirus thought to be the etiological agent of three human
malignancies: Kaposi’s sarcoma, multicentric Castleman’s disease
(MCD), and primary effusion lymphoma (PEL) (1–3). Like all
herpesviruses, KSHV is capable of establishing lifelong latent in-
fection within the host. In order to establish and maintain infec-
tion, KSHV must evade the host immune response. The primary
innate antiviral response is mediated by type I interferons (IFN-
and -) and results in increased antigen presentation, degradation
of viral RNA, cessation of protein processing, and apoptosis (4).
Type I IFNs are induced following viral detection of pattern-asso-
ciated molecular patterns (PAMPs) by pattern recognition recep-
tors (PRRs), such as Toll-like receptors (TLRs) (5).
The TLRs most commonly associated with the detection of
viral infection include TLR3, -7, -8, and -9 (5). TLR3 resides in
cellular endosomes where it recognizes double-stranded RNA
(dsRNA) (5). Upon ligand binding, TLR3 signals through the
adaptor protein toll/interleukin-1 receptor (TIR)-domain-con-
taining adaptor-inducing beta interferon (TRIF) and ultimately
results in the activation of cellular interferon regulatory factors
(IRFs). Two major IRFs, IRF3 and IRF7, are responsible for the
induction of type I IFN. Upon activation, IRF3 and IRF7 are phos-
phorylated, can hetero- or homodimerize, and subsequently
translocate to the nucleus, where they activate an antiviral tran-
scription program.
We have previously shown that TLR3 is upregulated in response
to primary KSHV infection in human monocytes (6). Others have
shown that infection of endothelial cells with KSHV suppresses the
expression of TLR4, which recognizes lipopolysaccharides (LPSs)
(7). Furthermore, our group has demonstrated that the stimula-
tion of TLR7 and TLR8 leads to reactivation and the production of
infectious KSHV in latently infected PEL cells (8). Therefore, the
interactions between KSHV and TLRs appear to play an impor-
tant role in KSHV infection and progression.
KSHV encodes multiple homologs of cellular immune proteins,
including four homologs of the cellular IRFs, known as viral IRFs
(vIRFs), which have been shown to be multifunctional. These four
viral proteins are encoded by K9 (vIRF1), K11 and K11.1 (vIRF2),
K10.5 and K10.6 (vIRF3), and K10 (vIRF4) (reviewed in reference 9).
vIRF1, -2, and -4 are primarily lytic proteins, while vIRF3, also known
as latency-associated nuclear antigen 2 (LANA-2), is expressed dur-
ing latency (9, 10). KSHV vIRFs perform a variety of functions, in-
cluding inhibition of p53 (10–14), Myc (15, 16), Notch (17), trans-
forming growth factor (TGF-) (18), and apoptosis (19–23). Of the
four vIRFs, vIRF1, -2, and -3 have been shown to inhibit the IFN
response (24–33). In these reports, IFN was activated by the expres-
sion of a cellular IRF, treatment with IFN, or viral infection, and
blockade of the IFN response was primarily measured by reporter
assays. However, it remains unclear whether vIRFs are able to block
IFN responses initiated by TLR activation and if the vIRFs are redun-
dant or specific in their abilities to inhibit a particular TLR pathway.
Additionally, studies have yet to compare the abilities of vIRF1, -2,
and -3 to block IFN responses. Furthermore, while several other
groups have examined the ability of KSHV vIRFs to block IFN induc-
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tion upon viral infection (25, 30, 31, 34, 35), we are the only ones to
have described the effect of vIRF expression on levels of viral replica-
tion in the context of vIRF2 (36).
Primary KSHV infection of monocytes results in increased
TLR3, CXC chemokine ligand 10 (CXCL10), and IFN- message
levels early after infection (6). In this report, we demonstrate that
at later time points postinfection, TLR3 and CXCL10 transcripts
are downregulated, suggesting that viral genes might contribute to
suppression of the innate immune response as the infection pro-
cess progresses. We demonstrate that KSHV vIRF1, -2, and -3
display differences in their abilities to block IFN signaling medi-
ated by TLR3. TLR3-mediated activation of IFN transcription re-
porters was inhibited by the expression of vIRF1, -2, and -3. How-
ever, only vIRF1 and vIRF2 inhibited IFN- message and protein
levels. Furthermore, vIRF1 and vIRF2 may block TLR3-mediated
signaling via different mechanisms. We also compared the ability
of each vIRF to inhibit viral replication of encephalomyocarditis
virus (EMCV), a virus that is known to be sensitive to IFN. The
expression of vIRF1 or vIRF2 rescued EMCV replication. Collec-
tively, our data suggest that the KSHV vIRFs can block TLR3-
mediated IFN induction and that each vIRF is unique in its ability
to block TLR3-mediated antiviral immune responses.
MATERIALS AND METHODS
Plasmids. pcDNA3 vIRF1-cMyc and pcDNA3 vIRF3-FLAG were gener-
ous gifts of Jae Jung (University of Southern California, Los Angeles, CA),
pcDNA4/vIRF2 was as described previously (28), IRF3 and interferon-
stimulated regulatory element (ISRE) Luc (37) were generous gifts of
Joseph Pagano (University of North Carolina, Chapel Hill), and pIFN--
luc (38) was a generous gift of Zhijian Chen (University of Texas South-
western, Dallas TX). The QuikChange XL II site-directed mutagenesis kit
(Stratagene) and the pcDNA3.1 directional Topo expression kit (Invitro-
gen) were utilized to generate the pcDNA3 vIRF1-FLAG and pcDNA3
vIRF2-FLAG constructs.
Cell cultures. KSHV-THP1 cell lines were generated and maintained
as described previously (39). Briefly, THP1 monocytes were infected with
recombinant KSHV.219 (rKSHV.219) and maintained in 0.1 g/ml pu-
romycin. 293-TLR3 cells and control 293 cells (InvivoGen) were cultured
at 37°C with 5% CO2 in Dulbecco’s modified Eagle medium (DMEM)
(Cellgro) supplemented with 10% heat-inactivated fetal bovine serum
(FBS) (Cellgro), 100 U/ml each of penicillin and streptomycin, 2 mM
L-glutamine, and 10 g/ml blasticidin S (InvivoGen). To activate TLR3
signaling,cellsweretreatedwithhigh-molecular-weightpoly(I·C)(Invivo-
Gen) at 20 g/ml for the indicated times. Cells were transfected with
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s in-
structions.
Immunoblotting. Upon harvesting, cells were washed once with
phosphate-buffered saline (PBS) and lysed in radioimmunoprecipitation
assay (RIPA) buffer with the addition of protease inhibitor complete tabs
(Roche) and phosphatase inhibitor cocktail I and II (Sigma). Protein con-
centrations were determined by Bradford assays (Bio-Rad), and equal
amounts of proteins were separated using SDS-PAGE and transferred
onto Hybond-ECL nitrocellulose membranes (GE Healthcare). The anti-
bodies we used included anti-Myc-horseradish peroxidase (HRP) (Invit-
rogen), anti-Xpress (Invitrogen), anti-ECS-HRP (Bethyl), anti-phospho-
IRF3 (Ser396) (Cell Signaling Technology), IRF3 (Cell Signaling
Technology), and actin (Santa Cruz Biotechnology). Blots were exposed
to the appropriate secondary antibodies conjugated to horseradish perox-
idase when necessary and visualized using chemiluminescence (GE Cor-
poration).
Quantitative real-time PCR. RNA was isolated with the RNeasy Plus
minikit or the RNeasy microkit (Qiagen) according to the manufacturer’s
instructions and as described previously (6, 40). Reverse transcription was
performed using Moloney murine leukemia virus (MMLV) reverse trans-
criptase (Invitrogen) and random hexamer primers (Invitrogen). Real-
time PCR (RT-PCR) was performed on an ABI 7300 using SYBR green
PCR master mix (Applied Biosystems). PCR was carried out with 1 cycle
of 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15
s and 60°C for 1 min. All fold activations were normalized to that of
-actin. The primer sequences used were 5=-GATCTGTCTCATAATGG
CTTG (forward) and 5=-GACAGATTCCGAATGCTTGTG (reverse) for
TLR3, 5=-GGAACCTCCAGTCTCAGCACC (forward) and 5=-CAGCCT
CTGTGTGGTCCAATCC (reverse) for CXCL10, 5=-CAGCAATTTTCA
GTGTCAGAAGC (forward) and 5=-TCATCCTGTCCTTGAGGCAGT
(reverse) for IFN-, 5=-GTCGTGAAGGAAGCAGT (forward) and 5=-C
ACGTGGCTTTTGGCCGCAGAGGC (reverse) for EMCV, and 5=-TCA
TGAAGTGTGACGTGGACATC (forward) and 5=-CAGGAGGAGCAAT
GATCTTGATCT (reverse) for -actin (41).
Luciferase assays. Cells were lysed with reporter lysis buffer (Pro-
mega) for 1 h on ice, and luciferase assays were performed with a luciferase
assay system (Promega) according to the manufacturer’s instructions.
The results were read using a FLUOstar Optima (BMG Labtech) micro-
plate reader and normalized to total protein as determined by the Brad-
ford assay (Bio-Rad).
IFN- ELISA. Supernatants were exposed to an enzyme-linked im-
munosorbent assay (ELISA) specific for IFN- (human origin; PBL Inter-
feron Source) per the manufacturer’s instructions. Absorbance at 450 nm
was read on a VersaMax tunable microplate reader (Molecular Devices).
The standard provided by the manufacturer was plotted with a 4-param-
eter fit, and the concentration for each sample was determined based on
the standard curve.
Immunofluorescence assay. 293-TLR3 cells were plated directly onto
coverslips placed in 6-well dishes. After the indicated treatment, the cov-
erslips were washed with PBS and fixed for 15 min with 3% paraformal-
dehyde. The cells were then washed 3 times in PBS for 5 min each and
placed in 10% goat serum (Vector Laboratories) and 0.2% Triton X-100
in PBS for 1 h at room temperature. Then, cells were washed once in 2%
bovine serum albumin (BSA) (Sigma) in PBS before the addition of a
1:100 dilution of anti-IRF3 (Cell Signaling Technology) in 10% goat se-
rum in PBS. Primary antibody incubation was performed at 4°C over-
night. The coverslips were then washed 3 times for 5 min each in 2% BSA
in PBS, and anti-rabbit Alexa Fluor 488 (Invitrogen) was added at a dilu-
tion of 1:500. Following secondary antibody incubation for 1 h at room
temperature, cells were washed 3 times in 2% BSA in PBS for 5 min each,
and the coverslips were allowed to air dry before being mounted onto
slides with Prolong Gold antifade reagent with 4=,6-diamidino-2-phe-
nylindole (DAPI) (Invitrogen).
Slides were examined on a Nikon Eclipse Ti microscope using Nikon
Elements software. Images were taken using the same settings, and con-
trast adjustments were applied equally to all images.
Viral infections and plaque assays. KSHV was produced as described
previously using Vero cells containing latent rKSHV.219 (KSHV-Vero)
and a recombinant baculovirus KSHV Orf50 (Bac50), kindly provided by
Jeffrey Vieira (42). KSHV infection was performed as described previously
(39, 40).
To produce EMCV, a baby hamster kidney (BHK)-21 cell monolayer
was infected at a multiplicity of infection (MOI) of 10 with EMCV (ATCC
VR-1762) for 24 h. Supernatants were harvested, subjected to centrifuga-
tion for 30 min at 10,000 rpm, aliquoted, and stored at 80°C. Viral titers
were quantified on L929 cells by standard plaque assays as described pre-
viously (43). Infection of 293-TLR3 cells was performed in 12-well Cell-
Bind dishes (Corning) by applying 200 l virus at the indicated MOI in
complete medium for 1 h, after which an additional 800 l complete
medium was added to the cells. Twenty-four hours postinfection, cells
and supernatants were harvested. EMCV plaque assays were performed
on L929 cells by the addition of 200 l serially diluted viral supernatant
and incubation for 1 h prior to the addition of 2 MEM medium mixed
1:1 with 2.5% carboxymethylcellulose (Sigma). Cells were incubated for
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24 h, and then plaques were washed 1 time with water before being stained
with 0.25% crystal violet and counted.
RESULTS
TLR3 levels are modulated by KSHV infection in monocytic
cells. Our previous work indicated that upon primary KSHV infec-
tion of the THP1 monocytic cell line, expression of TLR3 mRNA is
upregulated approximately 8- to 15-fold compared to that for mock-
infected cells (6). This increase in TLR3 expression was concomitant
with increases in downstream TLR3 effectors, CXCL10, IFN-, and
CC chemokine ligand 2 (CCL2), at 16 h postinfection (6). In order to
determine whether TLR3 upregulation was maintained postinfec-
tion, THP1 monocytic cells were infected with KSHV, and the relative
levels of TLR3 message were determined by quantitative RT-PCR at
multiple time points. TLR3 message levels initially increased, as seen
at 16 h postinfection (6); however, at 48 h postinfection, TLR3 mes-
sage levels declined (Fig. 1A). By 120 h postinfection, TLR3 message
levels had decreased to a level similar to that seen in latently infected
KSHV-THP1 cells (39). The same pattern was seen with CXCL10, a
chemokine downstream of TLR3 (Fig. 1B). These data suggest that
KSHV infection induces a host response, as reflected by increases in
TLR3 and CXCL10 transcripts early after infection, but that the levels
of these transcripts are downregulated over time.
vIRF1, -2, and -3 inhibit TLR3-activated interferon promoter
elements. KSHV downregulation of TLR3 and its downstream
responses suggests that TLR3 may be a target of KSHV immune
inhibition. As both vIRF1 and vIRF3 transcripts can be detected in
latently infected monocytes (39), we hypothesized that KSHV
vIRFs may antagonize TLR3 signaling to reduce immune detec-
tion. Furthermore, it remains unclear if the vIRFs are redundant
or have unique functions in blocking IFN signaling. To address
and compare the ability of vIRFs to inhibit TLR3 signaling, 293
cells stably expressing TLR3 and control 293 cells were cotrans-
fected with the control vector or vectors expressing vIRF1, -2, or -3
together with an ISRE luciferase reporter. Twenty-four hours
posttransfection, cells were stimulated with poly(I·C), a double-
stranded RNA analogue and ligand for TLR3. All three vIRFs
blocked the ISRE reporter activity induced by TLR3 (Fig. 2A). To
confirm this result, a different reporter construct containing the
entire human IFN- promoter was cotransfected with the vIRFs
(38). Expression of all three vIRFs decreased transcription of this
reporter compared to transcription in vector control-expressing
cells (Fig. 2B). All three vIRF proteins were adequately expressed
prior to assessment of promoter activity (Fig. 2C). These data
indicate that vIRF1, -2, and -3 inhibit TLR3-driven IFN promoter
activation.
vIRF1 and vIRF2 block production of IFN- message and
protein. To further assess vIRF1, -2, and -3 blockade of TLR3-
mediated interferon responses, we examined the transcript levels
of CXCL10, IFN-, and IFN- activated by TLR3 ligation. 293-
TLR3 cells were transfected with an empty vector control or with
vectors expressing vIRF1, -2, or -3 for 24 h followed by stimulation
with poly(I·C). Response to the ligand was assessed by quantita-
tive RT-PCR measurement of CXCL10, IFN-, and IFN- mes-
sage levels normalized to that of the -actin control and compared
to vector-untreated cells. Expression of vIRF1 and vIRF2 resulted
in decreased levels of CXCL10 message compared to those of the
vector control and vIRF3 poly(I·C)-stimulated cells (Fig. 3A).
Similarly, while IFN- was only marginally induced by TLR3
ligation, vIRF1 was able to suppress this increase (Fig. 3B).
Furthermore, vIRF1 and vIRF2 inhibited the increase in IFN-
message levels mediated by poly(I·C) treatment, while vIRF3
expression did not reduce IFN- message levels (Fig. 3C).
Next, we examined production and secretion of IFN- by
ELISA. To eliminate potential vector effects, all vIRFs were
expressed from the same pcDNA3 vector and tagged with the
FLAG epitope. Expression of either vIRF1 or vIRF2 signifi-
cantly decreased TLR3-mediated IFN- production, while
vIRF3 expression had little effect (Fig. 3D). The inability of
vIRF3 to block poly(I·C)-mediated IFN- production in this
cell type was not due to low vIRF3 expression levels, as vIRF2
expression appeared to be lower than that of vIRF3 (Fig. 3E).
These data demonstrate that the vIRFs have a differential abil-
ity to block TLR3-induced IFN responses.
Next, we assessed the ability of vIRFs to block induction of
TLR3 from a biological ligand. For these studies, we utilized the
encephalomyocarditis virus, a single-stranded RNA virus within
the Picornaviridae family. During EMCV replication, dsRNA is
produced (44), which can activate TLR3 (45). 293-TLR3 cells were
transfected with the control vector or vectors expressing vIRF1, -2,
or -3. Twenty-four hours after transfection, cells were infected
with EMCV; 24 h postinfection, cells were harvested, and the pro-
duction of IFN- message was determined by quantitative RT-
FIG 1 KSHV infection leads to decreased TLR3 and CXCL10 message levels.
THP1 monocytic cells were infected with KSHV and harvested at the indicated
time points. Latently infected KSHV-THP1 cells maintained under selection
were harvested concurrently as controls. RNA was isolated from cells, and
relative message levels were determined by quantitative RT-PCR. TLR3 (A)
and CXCL10 (B) message levels were normalized to that of -actin and are
represented as fold increases over those of mock-infected monocytes after
normalization. Values represent the means plus or minus the standard devia-
tions of the means from duplicate biological replicates. *, P  0.02; **, P 
0.005; and ***, P  0.002 (by Student’s t test).
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PCR. EMCV infection resulted in a 100-fold increase in the
IFN- message level compared to that of the mock-infected cells;
expression of vIRF1 and vIRF2 inhibited this increase in IFN-
message levels, while vIRF3 did not have a significant effect on IFN
mRNA induction (Fig. 3F).
vIRF1 inhibits IFN response by inhibiting IRF3. The data pre-
sented above indicate that not all vIRFs block TLR3-mediated IFN
responses equally, suggesting that the mechanisms by which the
vIRFs inhibit IFN may be different. Currently, the mechanism of
vIRF1 inhibition of IFN is best understood. vIRF1 is known to bind to
cellular IRF1 (25, 33), IRF3, and IRF7 (34). Most notably, vIRF1 in-
teraction with IRF3 inhibited IRF3-mediated transcription (34). This
seems to occur through vIRF1 blockade of IRF3 cotranscription fac-
tors p300 and p300/CBP-associated factor (PCAF) (25, 34, 46, 47).
To elucidate how vIRFs block TLR3-mediated IFN expression, we
examined phosphorylation of IRF3 in 293-TLR3 cells expressing
vIRFs or the control vector. Following poly(I·C) treatment, phos-
phorylation of IRF3 increased dramatically, and this increase was re-
duced to unstimulated levels by expression of vIRF1 but not vIRF2 or
vIRF3 (Fig. 4A). Changes in phosphorylation were not due to changes
in total IRF3 protein, as IRF3 levels remained unchanged regardless of
poly(I·C) treatment. Furthermore, the expression of vIRF1 seemed to
reduce IRF3 nuclear localization upon poly(I·C) treatment compared
to the vector, vIRF2, and vIRF3 (Fig. 4B). These data suggest that
while vIRF1 and vIRF2 both inhibit TLR3-mediated increases in
IFN-, they may accomplish this via different mechanisms.
To address the ability of vIRF1 to block activation of cellular
IRF3, cells were cotransfected with the control vector or vectors
expressing vIRF1, -2, or -3 and an IRF3 expression plasmid or an
empty control. Upon poly(I·C) treatment, all three vIRFs were
able to significantly reduce IFN- production when IRF3 was ex-
pressed (Fig. 4C). vIRF1 was able to decrease IFN- expression to
the highest degree. These data suggest that vIRF1 inhibits TLR3-
mediated interferon responses by preventing IRF3 phosphoryla-
tion and nuclear translocation.
Expression of vIRF1 and vIRF2 results in increased EMCV
replication. To address the significance of vIRF blockade of IFN
signaling and viral replication, we utilized EMCV-mediated acti-
vation of TLR3. 293-TLR3 cells were transfected with the control
vector or vectors expressing vIRF1, -2, or -3. One day after trans-
fection, cells were infected with EMCV, and cells and supernatants
were harvested 24 h postinfection to assess EMCV viral genomic
load by RT-PCR and infectious titers by plaque assay. Expression
of the vIRFs alone did not affect EMCV replication (Fig. 5A and
B), and their expression was confirmed by immunoblotting (Fig.
5C). This result is in concordance with that in our previous report,
demonstrating that vIRF2 had no effect on EMCV replication
compared to that of the control (36).
While the expression of the individual KSHV vIRFs had no
effect on EMCV replication, it remained a possibility that the
infection overwhelmed vIRF inhibition of immune responses.
Therefore, cells were treated with poly(I·C) for 6 h prior to
infection with EMCV to activate TLR3-mediated immune sig-
naling. EMCV replication in cells pretreated with poly(I·C) and
expressing either vIRF1 or vIRF2 was rescued as determined by
increased viral RNA and production of infectious particles
compared to those of the vector control (Fig. 6A and B). In
contrast, cells expressing vIRF3 exhibited a statistically signif-
icant decrease in viral RNA and infectious particle production
(Fig. 6A and B). This alteration in EMCV replication was not
due to altered expression of the vIRFs (Fig. 6C). Together, these
data suggest that vIRF1- and vIRF2-mediated blockade of the
immune response may allow for more efficient infection by
pathogens that activate TLR3. In contrast, vIRF3 expression
did not affect EMCV viral replication.
FIG 2 vIRF1, -2, and -3 block activation of IFN-responsive promoters. 293
and 293-TLR3 cells were transfected with the control vector or vectors express-
ing vIRF1, -2, or -3 and cotransfected with ISRE (A) or pIFN- (B) luciferase
reporters. Twenty-four hours posttransfection, cells were treated with
poly(I·C) for 24 h and harvested. Luciferase activity was measured and nor-
malized to total protein content. (C) Lysates harvested 24 h after poly(I·C)
treatment were subjected to SDS-PAGE and immunoblotted with the epitope
tags Myc (vIRF1), Xpress (vIRF2), and FLAG (vIRF3) to determine the expres-
sion levels of vIRFs posttransfection. Values represent the means plus or minus
the standard deviations of the means from triplicate samples. *, P  0.02 (by
Student’s t test).
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DISCUSSION
In summary, KSHV vIRF1, -2, and -3 displayed differences in their
abilities to block interferon signaling induced by TLR3. At early
time points following primary KSHV infection, TLR3 and
CXCL10 message levels were increased in monocytes (6), but at
later times these message levels decreased, suggesting that KSHV is
capable of counteracting the host innate immune response to viral
infection. Expression of KSHV vIRF1, -2, or -3 resulted in a block-
ade of TLR3-mediated activation of IFN-responsive promoter re-
porters. However, only vIRF1 and vIRF2 inhibited increases in
both IFN- message and protein levels in response to TLR3 acti-
vation. We found that vIRF1 but not vIRF2 or vIRF3 led to de-
FIG 3 vIRF1 and vIRF2 block TLR3-mediated transcription and production of IFN-. 293-TLR3 cells were transfected with the control vector or vectors
expressing vIRF1, -2, or -3. Twenty-four hours posttransfection, cells were treated with poly(I·C) for 14 h, and cells were harvested for analysis by quantitative
RT-PCR. Relative CXCL10 (A), IFN- (B), and IFN- (C) message levels were normalized to that of -actin and represented as fold increases over those of
untreated cells. (D and E) Cells were transfected with pcDNA3 vIRF-FLAG constructs or empty pcDNA3 vector as the control. Twenty-four hours posttrans-
fection, cells were treated with poly(I·C), and cells and supernatants were harvested 24 h later. (D) Supernatants were quantitated for secreted IFN- levels by
ELISA. (E) Lysed cells were subjected to SDS-PAGE and immunoblotted with anti-FLAG to determine expression levels of vIRFs posttransfection. The asterisks
denote nonspecific bands. (F) 293-TLR3 cells were transfected with control vector or vIRF1, -2, or -3. One day posttransfection, cells were infected with EMCV
at an MOI of 0.1 for 24 h before harvesting. Quantitative RT-PCR was performed on RNA isolated from EMCV-infected cells to assess IFN- message levels
normalized to that of -actin, represented as fold increase over control vector mock-infected cells. Values represent the means plus or minus the standard
deviations of the means from triplicate samples. *, P  0.03, and **, P  0.02 (by Student’s t test).
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creased phosphorylation and nuclear translocation of IRF3 in re-
sponse to TLR3 activation. This suggests that the mechanisms by
which the vIRFs reduce IFN activation may be different. Further-
more, vIRF1 and vIRF2 may block TLR3-mediating signaling via
different mechanisms. Following infection with EMCV, the ex-
pression of vIRF1 and vIRF2 but not vIRF3 resulted in decreased
production of IFN- and corresponded with increased viral pro-
duction when cells were pretreated with poly(I·C). While others
have previously determined the ability of vIRFs to inhibit the in-
duction of IFN upon viral infection (25, 30, 31, 34, 35), this study
is the first to compare the impact of expression of different vIRFs
on viral replication.
KSHV and its macaque homolog, rhesus macaque rhadinovi-
rus (RRV), are the only viruses known to encode proteins with
homology to cellular IRFs (48–50). Recently, an RRV knockout
virus was generated in which all copies of vIRFs were removed
(51). Infection of rhesus macaque peripheral blood mononuclear
cells or fibroblasts with vIRF knockout RRV resulted in the in-
creased induction of type I and II IFN compared to infection with
wild-type RRV (51). Furthermore, IRF3 phosphorylation and nu-
FIG 4 vIRF1 expression inhibits IRF3 downstream of TLR3. (A) 293 and 293-TLR3 cells were transfected with the control vector or vectors expressing vIRF1,
-2, or -3. Twenty-four hours posttransfection, cells were treated with poly(I·C) for 16 h before cells were harvested, lysed, and subjected to immunoblotting. (B)
293-TLR3 cells were transfected with the control vector or vectors expressing vIRF1, -2, or -3, and 4 h posttransfection, cells were trypsinized and moved to 6-well
dishes containing coverslips. Twenty hours after replating, cells were treated with poly(I·C) for 1 h before coverslips were harvested and stained for IRF3 (shown
in green). DAPI staining is shown in blue. Arrows point to vIRF-expressing cells. (C) 293-TLR3 cells were transfected with a control vector or vIRF1, -2, or -3 and
cotransfected with control vector or cellular IRF3. One day posttransfection, cells were treated with poly(I·C) for 24 h before supernatants were harvested and
subjected to IFN- ELISA. Values represent the means plus or minus the standard deviations of the means of results from triplicate samples. *, P  0.05; **, P 
0.04; and ***, P  0.01 (by Student’s t test).
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clear accumulation were increased in knockout virus infection,
suggesting that at least one RRV vIRF targets IRF3 to modulate
type I IFN responses (51). Rhesus macaques infected with an RRV
deleted for the vIRFs exhibited sustained production of proin-
flammatory cytokines, decreased viral load, and diminished B cell
hyperplasia compared to those infected with the wild-type RRV
(52). A similar result was observed when PEL cells with silenced
KSHV vIRF1 expression were transferred into immunocompro-
mised mice. The mice that received cells with decreased vIRF1
expression exhibited higher levels of IRF3 and signal-transducing
activators of transcription 1 (STAT1) than mice given control cells
FIG 5 vIRF expression does not alter EMCV infectivity. 293-TLR3 cells were
transfected with the control vector or vectors expressing vIRF1, -2, or -3.
Twenty-four hours posttransfection, cells were infected with EMCV at an MOI
of 0.001 for 24 h before harvesting. (A) Quantitative RT-PCR was performed
on RNA to measure EMCV genetic material, normalized to that of -actin,
represented as the fold increase over vector mock-infected cells. (B) Plaque
assays were performed on L929 cells with six different 1:10 serial dilutions of
viral supernatant. (C) Lysates harvested at the time of EMCV infection were
subjected to SDS-PAGE and immunoblotted with the epitope tags Myc
(vIRF1), Xpress (vIRF2), and FLAG (vIRF3) to determine the expression levels
of vIRFs posttransfection. Values represent the means plus or minus the stan-
dard deviations of the means from triplicate biological replicates.
FIG 6 vIRF1 or vIRF2 expression leads to increased EMCV viral production
following poly(I·C) pretreatment. 293-TLR3 cells were transfected with the con-
trol vector or vectors expressing vIRF1, -2, or -3. Twenty-four hours posttransfec-
tion, cells were treated with poly(I·C) for 6 h prior to infection with EMCV at an
MOI of 0.001 for 24 h before harvesting. (A) Quantitative RT-PCR was performed
on RNA to investigate EMCV genetic material, normalized to that of -actin,
represented as the fold increase over vector mock-infected cells. (B) Plaque assays
were performed on L929 cells with six different 1:10 serial dilutions of viral super-
natant. (C) Lysates harvested at the time of EMCV infection were subjected to
SDS-PAGE and immunoblotted with the epitope tags Myc (vIRF1), Xpress
(vIRF2), and FLAG (vIRF3) to determine the expression levels of vIRFs posttrans-
fection. Values represent the means plus or minus the standard deviations of the
means from triplicate biological replicates. *, P  0.02 (Student’s t test).
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(53). These data indicate that vIRFs may have a profound impact
on viral infection and virus-related malignancies. Collectively, our
data suggest that KSHV vIRF1, -2, and -3 are able to differentially
inhibit IFN induction in a context-dependent TLR-specific man-
ner. We found that KSHV vIRF1 and vIRF2 but not vIRF3 could
inhibit TLR3-mediated interferon induction. These data raise the
possibility that each vIRF may show specificity in inhibiting inter-
feron signaling activated by a specific TLR.
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